Dr Reddys (Germany) Buy Hold or Sell Recommendation
| RDDA Stock | EUR 14.30 0.10 0.70% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Dr Reddys Laboratories is 'Cautious Hold'. Macroaxis provides Dr Reddys buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding RDDA positions.
Check out Dr Reddys Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as RDDA and provide practical buy, sell, or hold advice based on investors' constraints. Dr Reddys Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
RDDA |
Execute Dr Reddys Buy or Sell Advice
The RDDA recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Dr Reddys Laboratories. Macroaxis does not own or have any residual interests in Dr Reddys Laboratories or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Dr Reddys' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Dr Reddys Returns Distribution Density
The distribution of Dr Reddys' historical returns is an attempt to chart the uncertainty of Dr Reddys' future price movements. The chart of the probability distribution of Dr Reddys daily returns describes the distribution of returns around its average expected value. We use Dr Reddys Laboratories price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Dr Reddys returns is essential to provide solid investment advice for Dr Reddys.
| Mean Return | 0.05 | Value At Risk | -2.22 | Potential Upside | 2.84 | Standard Deviation | 1.55 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Dr Reddys historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Dr Reddys Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Dr Reddys or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Dr Reddys' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a RDDA stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.04 | |
β | Beta against Dow Jones | 0.35 | |
σ | Overall volatility | 1.55 | |
Ir | Information ratio | 0.01 |
Dr Reddys Volatility Alert
Dr Reddys Laboratories has relatively low volatility with skewness of 0.05 and kurtosis of -0.3. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Dr Reddys' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Dr Reddys' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Dr Reddys Fundamentals Vs Peers
Comparing Dr Reddys' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Dr Reddys' direct or indirect competition across all of the common fundamentals between Dr Reddys and the related equities. This way, we can detect undervalued stocks with similar characteristics as Dr Reddys or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Dr Reddys' fundamental indicators could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Dr Reddys to competition |
| Fundamentals | Dr Reddys | Peer Average |
| Return On Equity | 0.18 | -0.31 |
| Return On Asset | 0.0949 | -0.14 |
| Profit Margin | 0.15 % | (1.27) % |
| Operating Margin | 0.19 % | (5.51) % |
| Current Valuation | 8.47 B | 16.62 B |
| Shares Outstanding | 166.1 M | 571.82 M |
| Shares Owned By Institutions | 10.37 % | 39.21 % |
| Price To Earning | 23.95 X | 28.72 X |
| Price To Book | 3.61 X | 9.51 X |
| Price To Sales | 0.04 X | 11.42 X |
| Revenue | 214.39 B | 9.43 B |
| Gross Profit | 113.84 B | 27.38 B |
| EBITDA | 48.86 B | 3.9 B |
| Net Income | 23.57 B | 570.98 M |
| Cash And Equivalents | 306.55 M | 2.7 B |
| Cash Per Share | 1.85 X | 5.01 X |
| Total Debt | 5.75 B | 5.32 B |
| Debt To Equity | 23.50 % | 48.70 % |
| Current Ratio | 1.89 X | 2.16 X |
| Book Value Per Share | 1,326 X | 1.93 K |
| Cash Flow From Operations | 28.11 B | 971.22 M |
| Earnings Per Share | 2.47 X | 3.12 X |
| Price To Earnings To Growth | 1.50 X | 4.89 X |
| Target Price | 77.85 | |
| Number Of Employees | 24.8 K | 18.84 K |
| Beta | 0.24 | -0.15 |
| Market Capitalization | 8.14 B | 19.03 B |
| Total Asset | 296.65 B | 29.47 B |
| Z Score | 0.6 | 8.72 |
| Annual Yield | 0.01 % | |
| Five Year Return | 0.71 % | |
| Net Asset | 296.65 B | |
| Last Dividend Paid | 30.0 |
Dr Reddys Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as RDDA . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 14.3 | |||
| Day Typical Price | 14.3 | |||
| Price Action Indicator | 0.05 | |||
| Period Momentum Indicator | 0.1 |
About Dr Reddys Buy or Sell Advice
When is the right time to buy or sell Dr Reddys Laboratories? Buying financial instruments such as RDDA Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Dr Reddys in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency Thematic Idea Now
Cryptocurrency
Dynamically computed list of top cryptocurrencies sorted bymarket capitalization. The Cryptocurrency theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in RDDA Stock
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Dr Reddys Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.